Latest / Breaking News To Trading Moves
Samsung Biologics: Strategic Localization and Pharma Tariff Resilience
Samsung Biologics buys GSK’s Maryland drug facility for $280M as pharma tariffs loom
A major biomanufacturing footprint just moved onto US soil. Samsung Biologics is buying a drug production site in Rockville, Maryland from GSK for $280M, with plans to expand capacity and upgrade technology. The deal is expected to close by end of Q1 2026, and it plugs directly into the bigger theme: companies racing to “localise” pharma supply chains in case new US import tariffs hit.
What happened
Samsung Biologics America will acquire 100% of Human Genome Sciences Inc in Rockville, Maryland (a US drug…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.